Hyo Bin You

Mr. Hyo Bin You

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AAAbudumijiti Aibaidula
Abudumijiti Aibaidula
ALAli Gharibi Loron
Ali Gharibi Loron
SBSamantha M. Bouchal
Samantha M. Bouchal
MBMegan M. J. Bauman
Megan M. J. Bauman
HYHyo Bin You
Hyo Bin You
IPIan F. Parney
Ian F. Parney
Glioblastoma (GBM), the most common primary malignant brain tumor in adults, has a median survival of 14–15 months despite aggressive treatment. Monitoring relies on MRI, but differentiating tumor progression from pseudo-progression or radiation necrosis remains difficult. Plasma extracellular vesicles (EVs) are emerging as promising non-invasive biomarkers due to their molecular cargos and accessibility. This review evaluates studies that specifically isolated plasma EVs for molecular profiling in GBM diagnosis and monitoring. Biomarkers (miRNA, RNA, DNA, proteins), EV characterization methods, and advancements in enriching tumor-derived EV subpopulations and assessing their diagnostic and prognostic potential are highlighted. Plasma EVs carry diverse cargos, including miRNAs (e.g., miR-21, miR-15b-3p), mRNAs (e.g., EGFRvIII), circRNAs, and proteins (e.g., CD44, GFAP). Composite molecular signatures have achieved sensitivities of 87–100% and specificities of 73–100% for GBM diagnosis. Tumor-derived EVs, enriched using techniques like SEC-CD44 immunoprecipitation, microfluidic platforms, or 5-ALA-induced PpIX fluorescence, enhance biomarker detection. Non-tumor-derived EVs may also reflect GBM’s systemic effects. Challenges include EV heterogeneity, non-EV contamination, and variable biomarker expression across studies. Plasma-EV-based liquid biopsies offer significant potential for GBM monitoring, with advanced enrichment methods improving tumor-specific biomarker detection. Standardizing isolation protocols and validating biomarkers in larger cohorts are critical for clinical translation.

27 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
JRJulian Simon Rechberger
Julian Simon Rechberger
STStephanie A. Toll
Stephanie A. Toll
SBSubhasree Biswas
Subhasree Biswas
HYHyo Bin You
Hyo Bin You
WCWilliam David Chow
William David Chow
SKSoumen Khatua
Soumen Khatua
Central nervous system (CNS) tumors are the leading cause of cancer-related mortality in children, with prognosis remaining dismal for some of these malignancies. Though the past two decades have seen advancements in surgery, radiation, and targeted therapy, major unresolved hurdles continue to undermine the therapeutic efficacy. These include challenges in suboptimal drug delivery through the blood–brain barrier (BBB), marked intra-tumoral molecular heterogeneity, and the elusive tumor microenvironment. Drug repurposing or re-tasking FDA-approved drugs with evidence of penetration into the CNS, using newer methods of intracranial drug delivery facilitating optimal drug exposure, has been an area of intense research. This could be a valuable tool, as most of these agents have already gone through the lengthy process of drug development and the evaluation of safety risks and the optimal pharmacokinetic profile. They can now be used and tested in clinics with an accelerated and different approach. Conclusions: The next-generation therapeutic strategy should prioritize repurposing oncologic and non-oncologic drugs that have been used for other indication, and have demonstrated robust preclinical activity against pediatric brain tumors. In combination with novel drug delivery techniques, these drugs could hold significant therapeutic promise in pediatric neurooncology.

11 July 2026 in BMC Medical Education
Verified
Journal Article
Open access
PDF file
HYHyo Bin You
Hyo Bin You
NLNatasha Lee
Natasha Lee
KSKrishna Sinha
Krishna Sinha
DLDevon Lynn
Devon Lynn
HKHarrison Katz
Harrison Katz
JBJesse Bracamonte
Jesse Bracamonte
Medical students may delay or forgo care because of time constraints, cost, confidentiality concerns, and fragmented access. Data describing healthcare uti